Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TISLELIZUMAB Cause Product prescribing issue? 5 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Product prescribing issue have been filed in association with TISLELIZUMAB (TEVIMBRA). This represents 0.1% of all adverse event reports for TISLELIZUMAB.

5
Reports of Product prescribing issue with TISLELIZUMAB
0.1%
of all TISLELIZUMAB reports
0
Deaths
5
Hospitalizations

How Dangerous Is Product prescribing issue From TISLELIZUMAB?

Of the 5 reports, 5 (100.0%) required hospitalization, and 1 (20.0%) were considered life-threatening.

Is Product prescribing issue Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TISLELIZUMAB. However, 5 reports have been filed with the FAERS database.

What Other Side Effects Does TISLELIZUMAB Cause?

Myelosuppression (2,142) White blood cell count decreased (327) Neutrophil count decreased (277) Hepatic function abnormal (221) Pruritus (213) Rash (208) Platelet count decreased (183) Pyrexia (175) Nausea (165) Diarrhoea (145)

What Other Drugs Cause Product prescribing issue?

DUPILUMAB (1,715) POLYETHYLENE GLYCOL 3350 (1,439) LENALIDOMIDE (948) OXYCODONE (646) RIVAROXABAN (359) ACETAMINOPHEN\OXYCODONE (347) ETONOGESTREL (311) ACETAMINOPHEN\HYDROCODONE (298) CERTOLIZUMAB PEGOL (297) CABOZANTINIB S-MALATE (294)

Which TISLELIZUMAB Alternatives Have Lower Product prescribing issue Risk?

TISLELIZUMAB vs TISOTUMAB VEDOTIN TISLELIZUMAB vs TISOTUMAB VEDOTIN-TFTV TISLELIZUMAB vs TITANIUM DIOXIDE\ZINC TISLELIZUMAB vs TIVICAY TISLELIZUMAB vs TIVOZANIB

Related Pages

TISLELIZUMAB Full Profile All Product prescribing issue Reports All Drugs Causing Product prescribing issue TISLELIZUMAB Demographics